Camilla Chong, MD

Chief Medical Officer
InflaRx GmbH
London, England, United Kingdom

Disclosure(s): InflaRx GmbH: Employee

Presentation(s):

• 85 - Improved Survival with Dual Immunomodulator Treatment of ARDS by blocking C5a and IL-6 Activity: Subanalysis from the PANAMO Study in Critically Ill COVID-19 Patients

  Thursday, October 17, 2024
  11:15 AM – 11:30 AM US PT